[
  {
    "ts": null,
    "headline": "GEHC or SYK: Which Is the Better Value Stock Right Now?",
    "summary": "GEHC vs. SYK: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=ec4fc3c084fe4f2813f9ed1a7e44b2526b246f3ab04ab0c0718aeb66076c8b9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770828004,
      "headline": "GEHC or SYK: Which Is the Better Value Stock Right Now?",
      "id": 139048121,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GEHC",
      "source": "Yahoo",
      "summary": "GEHC vs. SYK: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=ec4fc3c084fe4f2813f9ed1a7e44b2526b246f3ab04ab0c0718aeb66076c8b9c"
    }
  },
  {
    "ts": null,
    "headline": "5 Must-Read Analyst Questions From GE HealthCare’s Q4 Earnings Call",
    "summary": "GE HealthCare’s fourth quarter saw positive momentum, with the company surpassing Wall Street’s revenue and non-GAAP profit expectations. Management pointed to robust demand in pharmaceutical diagnostics and steady growth in imaging and advanced visualization solutions as key drivers. CEO Peter Arduini highlighted progress in bringing new products to market, including successful launches in Europe and advanced cardiovascular ultrasound systems. The company also benefited from large enterprise ag",
    "url": "https://finnhub.io/api/news?id=407cbe02910d8bd5c5f31eee9b05e2e9007c65b2686cfa0f8fa20710a453f30c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770788177,
      "headline": "5 Must-Read Analyst Questions From GE HealthCare’s Q4 Earnings Call",
      "id": 139042565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GEHC",
      "source": "Yahoo",
      "summary": "GE HealthCare’s fourth quarter saw positive momentum, with the company surpassing Wall Street’s revenue and non-GAAP profit expectations. Management pointed to robust demand in pharmaceutical diagnostics and steady growth in imaging and advanced visualization solutions as key drivers. CEO Peter Arduini highlighted progress in bringing new products to market, including successful launches in Europe and advanced cardiovascular ultrasound systems. The company also benefited from large enterprise ag",
      "url": "https://finnhub.io/api/news?id=407cbe02910d8bd5c5f31eee9b05e2e9007c65b2686cfa0f8fa20710a453f30c"
    }
  }
]